Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

11.82 -0.48 (-3.90%)
Streaming Delayed Price Updated: 1:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 318,117
Open 12.21
Bid (Size) 11.81 (2)
Ask (Size) 11.82 (1)
Prev. Close 12.30
Today's Range 11.78 - 12.31
52wk Range 6.000 - 19.51
Shares Outstanding 122,816,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
4 Analysts Have This to Say About NeoGenomics
Via Benzinga

Performance

YTD
+30.03%
+30.03%
1 Month
-22.08%
-22.08%
3 Month
-25.10%
-25.10%
6 Month
-30.02%
-30.02%
1 Year
+35.71%
+35.71%

More News

Read More
Earnings Scheduled For August 11, 2023
Via Benzinga
NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat
Via Benzinga
NeoGenomics Reports Second Quarter 2023 Results
Via ACCESSWIRE
NeoGenomics's Return On Capital Employed Insights
Via Benzinga
NeoGenomics: Q1 Earnings Insights
Via Benzinga
NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares Soar
Via Benzinga
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Via ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
Analyst Expectations for NeoGenomics's Future
Via Benzinga
NeoGenomics Reports First Quarter 2023 Results
Via ACCESSWIRE
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Earnings Scheduled For May 12, 2023
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
Via Benzinga
McKesson, ICU Medical, Novavax And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
Via ACCESSWIRE
NeoGenomics, Inc. (NASDAQ:NEO) Long Term Investor Alert: Investigation of Potential Wrongdoing
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.